Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIFIDO CO., LTD. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner working within 1 distinct art unit. The high concentration of the portfolio suggests a highly specific technical focus or an early stage of prosecution activity for the company. FERNANDEZ, SUSAN EMILY is identified as the busiest examiner for this company, currently overseeing 1 busiest examiner pending action. This represents the entirety of the company's active workload at the patent office.
The alignment between the total pending actions and the count assigned to the busiest examiner indicates that prosecution is currently centralized under a single individual. Practitioners should note that the 1 distinct art unit involved provides a narrow jurisdictional footprint for these filings. Because there is only 1 distinct examiner, the company can maintain a very direct and consistent prosecution dialogue. This centralized structure is typical for portfolios with a single active matter, allowing for a singular focus on the specific requirements and examination style of FERNANDEZ, SUSAN EMILY. The pending matter serves as the primary point of engagement between the company and the patent office within the Biotechnology & Pharmaceuticals sector. This concentration of the workload under a single individual in a single group simplifies the administrative burden of tracking these filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18975096 | COMPOSITION FOR AMELIORATING, PREVENTING OR TREATING SYSTEMIC SCLEROSIS AND PULMONARY FIBROSIS CONTAINING BIFIDOBACTERIUM LONGUM RAPO | FERNANDEZ, SUSAN EMILY | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18975096 | COMPOSITION FOR AMELIORATING, PREVENTING OR TREATING SYSTEMIC SCLEROSIS AND PULMONARY FIBROSIS CONTAINING BIFIDOBACTERIUM LONGUM RAPO | FERNANDEZ, SUSAN EMILY | 1651 | §102§103§112DP | Non-Final OA | — | Pending | Dec 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIFIDO CO., LTD. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Susan Emily Fernandez has the most, with 1 of BIFIDO CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
